Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM310 Long-term Treatment in Adult Atopic Dermatitis
CTR20211068Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started May 2021; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20211068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211068.